Nonalcoholic Fatty Liver Disease: The Epidemic Nobody Sees Coming
Nonalcoholic fatty liver disease, NAFLD, is now the most common chronic liver condition in India, affecting an estimated 9 to 32 percent of the general population, according to data published in the Journal of Clinical and Experimental Hepatology. The numbers are worse in urban centres, where refined carbohydrates, deep-fried snacks, and sedentary desk jobs have combined to deposit fat inside liver cells at a rate the organ cannot clear.
The progression is quiet. Fat accumulates. Inflammation follows. Over years, that inflammation lays down scar tissue, fibrosis, and fibrosis, left alone, becomes cirrhosis. The person feels tired, perhaps bloated, sometimes nothing at all. By the time an ultrasound catches it, a decade of silent damage may already be done.
What makes NAFLD particularly deceptive in the Indian context is body composition. Indian bodies tend to accumulate visceral fat, fat around the organs, at lower BMI thresholds than Western populations. A person who looks lean by standard charts may already have a metabolic profile that is driving fat into the liver.
Chronic Hepatitis B and C Infections
India carries one of the world's largest burdens of chronic hepatitis B infection, with roughly 40 million people affected. Hepatitis C adds several million more. Both viruses attack liver cells directly, triggering the inflammation-fibrosis-cirrhosis sequence that alcohol causes through a different mechanism but the same anatomical endpoint.
The critical problem is that chronic hepatitis infection produces no symptoms for years, sometimes decades. People contract hepatitis B at birth, mother to child transmission remains common in states with incomplete vaccination coverage, and carry it silently into adulthood. They do not drink. They eat reasonably. Their liver is still being destroyed.
Hepatitis C, transmitted through shared needles, unscreened blood transfusions, or inadequately sterilised dental and surgical equipment, follows the same silent course. A 2019 study in the Indian Journal of Gastroenterology found that a significant proportion of cirrhosis cases presenting at tertiary hospitals in North India had hepatitis B or C as the primary driver, with no alcohol history.
Metabolic Syndrome and Type 2 Diabetes
Insulin resistance sits at the centre of both type 2 diabetes and NAFLD. When cells stop responding to insulin efficiently, the liver compensates by producing more fat. That fat does not leave. It stays, oxidises, triggers inflammatory cytokines, and begins the scarring process.
India now has over 100 million people living with type 2 diabetes, according to the Indian Council of Medical Research's ICMR-INDIAB study. A large proportion of them will develop some degree of fatty liver. The subset who also have high triglycerides, low HDL cholesterol, and abdominal obesity, the cluster that defines metabolic syndrome, are at the highest risk of progression from fatty liver to fibrosis to cirrhosis.
The liver damage in this group often goes undetected because the conversation in the clinic is about blood sugar, not the organ processing it.
Autoimmune Hepatitis
Autoimmune hepatitis occurs when the immune system misidentifies liver cells as foreign and attacks them. It is not caused by a virus, a toxin, or a dietary habit. The trigger is the body's own defence mechanism turning against a specific tissue.
It predominantly affects women, often between the ages of 15 and 40. The condition can present with jaundice and fatigue in acute phases, but many cases smoulder at a low level for years, producing fibrosis gradually without any dramatic episode. Without a specific blood test, elevated immunoglobulin G, positive antinuclear antibodies, it is frequently misdiagnosed as viral hepatitis or dismissed as stress-related fatigue.
Left untreated, autoimmune hepatitis progresses to cirrhosis. Treated early with immunosuppressants, the liver can stabilise. The window between diagnosis and irreversible scarring is the entire difference in outcome.
Long-Term Medication Use and Herbal Supplements
Drug-induced liver injury is underreported in India for two reasons: the drugs causing it are often considered safe, and the herbal preparations delivering the damage are not thought of as drugs at all.
Long-term use of methotrexate, prescribed for rheumatoid arthritis and psoriasis, is a documented cause of hepatic fibrosis. Antituberculosis drugs, particularly isoniazid and pyrazinamide, carry hepatotoxic risk, and India's TB burden means millions of people cycle through these regimens every year. Painkillers taken daily for chronic back pain or arthritis, particularly diclofenac and other NSAIDs, add cumulative stress to liver cells.
On the supplement side, certain Ayurvedic formulations containing heavy metals, lead, mercury, arsenic, that have not been properly processed through the traditional shodhana purification method have been linked to liver toxicity in published case reports in Indian medical literature. Kava, found in some imported wellness products, is a known hepatotoxin. The assumption that natural means safe is doing measurable damage.
The liver processes everything that enters the bloodstream. It does not distinguish between a pharmaceutical and a plant extract. Both can scar it, slowly, without announcing themselves.
Cirrhosis diagnosed in a non-drinker is not a medical anomaly, it is the predictable result of conditions that are common, underprogrammed, and rarely connected to the organ they are destroying. The fat in the liver, the virus from a childhood birth, the blood sugar the clinic is managing, the tablet taken for the knee, none of them feel like a liver story until the liver is the only story left.
